UPDATE FROM ASCO 2023
UPDATE FROM ASCO 2023
How will your clinical decisions impact a patient at two key stages in their journey?
How will your clinical decisions impact a patient at two key stages in their journey?
In this interactive patient case study developed by independent experts, you'll meet a patient with TRK fusion-positive lung cancer at initial diagnosis and then again at disease progression two years later.
As you learn about the potential clinical management and treatment options, you'll get the chance to make clinical decisions and see how they impact the patient's trajectory.
Prof Frédérique PENAULT-LLORCA
Pathologist
University of Clermont-Ferrand
France
Frédérique PENAULT-LLORCA, MD, PhD, graduated as a medical specialist in pathology in 1993 and in oncology in 1995. Also, in 1995, she received a PhD from the Université d’Aix-Marseille II in cellular biology and microbiology, on the topic of HER2. Frédérique PENAULT-LLORCA is currently professor of pathology at the University of Clermont-Ferrand, CEO of the Comprehensive Regional Cancer Institute Centre Jean PERRIN, Clermont-Ferrand, France, deputy director of the research team INSERM 1240 IMoST, and head of the Molecular Biology Plateform at Centre Jean Perrin. She serves as vice-president of the UNICANCER group and chairs of the Immuno-Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies, with her main areas of expertise being female cancers. She co-chairs the French breast cancer guidelines of Nice-St Paul. Frédérique PENAULT-LLORCA has conducted various biomarkers-based research studies in breast, lung, digestive tract, prostate and thyroid cancer in relation to response to targeted therapies and immunotherapies. Frédérique PENAULT-LLORCA has participated to more than 469 peer-reviewed publications and several books on female cancers and pathologic testing methods and issues.
Prof Frédérique PENAULT-LLORCA has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Daiichi Sankyo, Roche, Seagreen, Novartis, Lilly, Gilead, Pfizer, MSD, BMS, Janssen
Prof. Dr. Ángel Cequier Fillat
Cardiologist
University of Barcelona
Spain
-Professor of Cardiology. University of Barcelona. -Senior Teacher. Division of Cardiology. Bellvitge University Hospital -President of the Spanish Society of Cardiology -Director Heart Disease Institute, Bellvitge University Hospital (2010-2019) -Head of the Cardiovascular Group Research. IDIBELL (Bellvitge Research Institute). Barcelona (2010-2019). -President Scientific Committee AMI Code in Catalonia (2014-2018). -Director of the International Course “Prevention and Treatment of Complications in Percutaneous Interventional Cardiology". -Barcelona 2004, 2006, 2008, 2010, 2012, 2014, 2016 and 2018. Education and training in Cardiology: -Graduate in Medicine (University of Barcelona) -Residence in Cardiology (Bellvitge University Hospital) -PhD (University of Barcelona - 1994) -MCCEFG: Medical Council of Canada. Ottawa. Canada. (1987) -ECFMG: Educational Commission for Foreign Medical Graduates. Philadelphia, Pennsylvania. USA (1987) -Clinical and Research Fellowship in Interventional Cardiology: Montreal Heart Institute. University of Montreal. Canada (1986-1988). Scientific and Research Activity: - Three hundred articles published in International and National Journals (New England Journal of Medicine, Lancet, Circulation, European Heart Journal, Journal American College of Cardiology, Revista Española de Cardiologia, etc - Twenty books or book chapters. - 8 directed Doctoral Theses, - 97 research projects, PI and National Coordinator in multiple clinical trials.
Prof. Dr. Ángel Cequier Fillat has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Prof. Dr. Zuzana Motovska
Cardiologist
Charles University
Czech Republic
Present Position and Address Head of the Division of Acute Cardiology Deputy Head of Department for the Research Cardiology Department Cardiocenter Third Faculty of Medicine, Charles University University Hospital Kralovské Vinohrady Prague, Czech Republic Post Graduate Degrees Appointed as Professor of Internal Medicine at the Charles University, Prague, Czech Republic European Society of Cardiology Activities Councilor of the ESC Board 2018-2020 Member of Working group on Thrombosis Member of Acute Cardiovascular Care Association National coordinator of the ACS-STEMI Registry EORP Fellowships / Honours Fellow of European Society of Cardiology (since 2007) Award given by the Ministry of Education, Youth and Sports of Czech Republic for extraordinary results in research, experimental development and innovation – awarded in the year 2015 Major Research Interest Acute coronary syndromes Acute cardiac care Antithrombotic therapy Cardiovascular disease in women Cardiogenic shock Major Scientific Activities Principal investigator (design, leadership, coordination): Multicenter randomized PRAGUE 8 study Multicenter randomized PRAGUE 18 study Multicenter double-blind randomized DAPT-SCHOCK-AMI (PRAGUE 23) study (ongoing)
Prof. Dr. Zuzana Motovska has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Media title 1
@ASCO23 | 60 min | May 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Media title 2
@ASCO23 | 29 min | May 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Media title 3
@ASCO23 | 15 min | May 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Brought to you by COR2ED in collaboration with the CONNECTs, groups of international experts working in oncology